Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/50—Pyridazines; Hydrogenated pyridazines
  • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism

Definitions

• PMM2 deficiency is responsible for the most common congenital disorder of glycosylation (CDG) (Van, S. E. et al., FEBS Lett. 1995, 377, 318-320, Ferreira, C. R. et al., J. Inherit. Metab. Dis. 2018, 41, 541-553).
• CDG congenital disorder of glycosylation
• PMM2-CDG is a multisystem, multi-organ disease because a minimal level of glycosylation is required at all times in all cells of the body, with different cell types and organs more or less vulnerable to the complex sequelae of hypoglycosylation. As the residual level of PMM2 enzymatic activity increases, the number and severity of organ systems affected decreases.
• PMM2-CDG Mutations in the gene encoding PMM2 are responsible for PMM2-CDG (Jaeken, J. et al., J Inherit Metab Dis. 2008, 31, 669-72), and more than 115 mutations in the PMM2 gene have been found that cause PMM2-CDG. All disease causing mutations appear to reduce the enzymatic activity of PMM2, leading to an insufficient amount of activated mannose to form oligosaccharides for normal protein glycosylation. PMM2-CDG is also known as CDG-1A or Jaeken syndrome. PMM2-CDG displays variable clinical progression and presentation, with affected individuals typically developing signs and symptoms during infancy. Organs that are affected by PMM2-CDG include brain, hver, gastrointestinal tract, heart and kidney.
• the AR inhibitor administered is not ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alconil, statil, berberine or SPR-210.
• the method for the treatment or prevention of PMM2-CDG excludes the administration of Epalrestat. In other examples, the method for the treatment or prevention of PMM2-CDG excludes the administration of Epalrestat and alpha-cyano-4-hydroxycinnamic acid.
• the subject to be treated in accordance with the methods disclosed herein can have classical pediatric clinical presentations such as developmental delay, severe encephalopathy with axial hypotonia, abnormal eye movements, psychomotor retardation and/or cerebellar hypoplasia.
• the subject to be treated in accordance with the methods disclosed herein can have hypogonadism, coagulation abnormalities and thrombotic events, retinitis pigmentosa and/or peripheral neuropathy.
• the disclosure relates to a method of treating
• this disclosure relates to the use of an AR inhibitor for the manufacture of a medicament for treating PMM2-CDG.
• the disclosure also relates to the use of an AR inhibitor (e.g., zopolrestat, epalrestat, compound of any one of Formulas (I)-(VI)) for the treatment of PMM2- CDG.
• an AR inhibitor e.g., zopolrestat, epalrestat, compound of any one of Formulas (I)-(VI)
• the disclosure also relates to an AR inhibitor (e.g., zopolrestat, epalrestat, compound of any one of Formulas (I)-(VI)) for the manufacture of a medicament for the treatment of PMM2-CDG.
• an AR inhibitor e.g., zopolrestat, epalrestat, compound of any one of Formulas (I)-(VI)
• a pharmaceutical formulation for the treatment of PMM2-CDG that contains an AR inhibitor (e.g., zopolrestat, epalrestat, compound of any one of Formulas (I)-(VI) as an active ingredient.
• FIG. 2 illustrates the activation of PMM2 activity in PMM2-CDG patient-derived fibroblasts treated with Compound B.
• This disclosure relates to the use of AR inhibitors for the treatment of
• reference to a “compound of Formula (I)” includes a single compound as well as two or more of the same or different compounds; reference to an “excipient” includes a single excipient as well as two or more of the same or different excipients, and the like.
• the word “about” means a range of plus or minus 10% of that value, e.g., “about 50” means 45 to 55, “about 25,000” means 22,500 to 27,500, etc., unless the context of the disclosure indicates otherwise, or is inconsistent with such an interpretation.
• “about 49, about 50, about 55, “about 50” means a range extending to less than half the interval(s) between the preceding and subsequent values, e.g., more than 49.5 to less than 52.5.
• the phrases “less than about” a value or “greater than about” a value should be understood in view of the definition of the term “about” provided herein.
• this disclosure includes descriptions of various components, groups of components, ranges and other elements of the broader disclosure. It is intended that such elements can be variously combined to provide additional embodiments of the disclosure. It is also intended that any disclosed features (e.g., substituent, analog, compound, structure, component) including individual members of any disclosed group, including any sub-ranges or combinations of sub-ranges within the group, may be excluded from the disclosure or any embodiments of the disclosure for any reason.
• any disclosed features e.g., substituent, analog, compound, structure, component
• any sub-ranges or combinations of sub-ranges within the group may be excluded from the disclosure or any embodiments of the disclosure for any reason.
• the disclosure relates to a method for the treatment of PMM2- CDG, comprising administering to a subject in need thereof a therapeutically effective amount of a compound that inhibits aldose reductase activity.
• the compound can be any suitable compound that inhibits AR activity, such as a small molecule compound (e.g., having a size of 5 kDa or less), a biologic agent (e.g., an inhibitory RNA directed against aldose reductase) or a combination thereof.
• the AR inhibitor is a small molecule compound. Suitable small molecule AR inhibitors are known in the art and are disclosed herein.
• the AR inhibitors can be administered in any suitable molecular form including pharmaceutically acceptable salts, solvates, prodrugs, and compounds that contain stable isotopic forms of one or more atoms, e.g., deuterium in place of hydrogen.
• the method for the treatment of PMM2-CDG comprises administering to a subject in need thereof a therapeutically effective amount of zopolrestat.
• the method for the treatment of PMM2-CDG comprises administering to a subject in need thereof an therapeutically effective amount of epalrestat.
• the method for the treatment of PMM2-CDG comprises administering to a subject in need thereof an therapeutically effective amount of an aldose reductase, wherein the aldose reductase inhibitor is not ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT-112, zopolrestat, zenarestat, BAL- AR18, AD-5467, M-79175, tolrestat, alconil, statil, berberine or SPR-210.
• the methods for the treatment of PMM2-CDG disclosed herein do not include administering epalrestat.
• the methods for the treatment of PMM2-CDG disclosed herein do not include administering epalrestat or alpha-cyano-4-hydroxycinnamic acid.
• the method for the treatment of PMM2-CDG comprises administering to a subject in need thereof an therapeutically effective amount of a compound of any one of Formulas (I)-(VI).
• the compound that is administered is Compound A or the compound that is administered is Compound B or a physiologically acceptable salt, hydrate, solvate or prodrug of Compound A or Compund B.
• the term “treating” refers to curative or palliative (e.g., control or mitigate a disease or disease symptoms) therapy. This can include reversing, reducing, arresting or delaying the symptoms, clinical signs, and underlying pathology of PMM2-CDG in a manner to improve or stabilize a subject’s condition.
• the method can be used for treatment of PMM2-CDG, treatment of complications (e.g., symptoms and clinical signs) of PMM2-CDG, and/or treatment and prevention of complications (e.g., symptoms and clinical signs) of PMM2-CDG.
• a therapeutically effective amount is an amount of a compound that is sufficient to achieve the desired therapeutic effect under the conditions of administration, such as an amount that reduces or ameliorates the severity of PMM2-CDG, that prevents the advancement of conditions or symptoms related to PMM2-CDG, or enhances or otherwise improves therapeutic effect(s) of another therapy for the treatment or management of PMM2-CDG.
• a therapeutically effective amount can be an amount that increases PMM2 enzymatic activity, in the subject being treated.
• the actual amount administered can be determined by an ordinarily skilled clinician based upon, for example, the subjects age, weight, sex, general heath and tolerance to drugs, severity of disease, dosage form selected, route of administration and other factors.
• the amount of an AR inhibitor that is administered is from about 0.5 to about 60 mg/kg body weight per day, such as from about 1.0 to 10 mg/kg.
• the therapeutically effective amount is an amount sufficient to reduce intracellular aldose reductase activity at least by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, e.g., about 100% (e.g., compared to pre-treatment level).
• the therapeutically effective amount can be an amount that increases PMM2 enzymatic activity at least by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 99%, or more, e.g., about 100% (e.g., compared to pre-treatment level).
• the therapeutically effective amount can be sufficient to restore PMM2 enzyme levels in a subject with PMM2-CDG.
• a “subject” can be any animal with PMM2-CDG, particularly a mammal, and including, but by no means limited to, humans, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, avian and porcine subjects, wild animals (whether in the wild or in a zoological garden), research or laboratory animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, and the like.
• a human subject to be treated using the methods disclosed herein is diagnosed with PMM2-CDG as a new bom through enzymatic or genetic screening, and has deficiency in PMM2 activity.
• This disclosure also relates to the prophylaxis or treatment of at least one clinical feature or complication of PMM2-CDG in a subject.
• Representative clinical features or complications which can be present in children, adolescents or adults, include, e.g., alternating internal strabism and other abnormal eye movements, axial hypotonia, intellectual disability, ataxia, and hyporeflexia. After infancy, symptoms include retinitis pigmentosa, often stroke-like episodes, and sometimes epilepsy.
• variable dysmorphy large, hypoplastic/dysplastic ears
• abnormal subcutaneous adipose-tissue distribution fat pads, inverted nipples
• mild to moderate hepatomegaly skeletal abnormalities (including atlantoaxial subluxation), and hypogonadism.
• Some infants develop pericardial effusion and/or cardiomyopathy.
• patients with a very mild phenotype no dysmorphy, very mild intellectual disability, ataxia
• Jaeken, J. et al, “Glycosylation and its Disorders: General Overview,” Elsevier, Reference Module in Biomedical Sciences, 2016 Jaeken, J. et al, “Glycosylation and its Disorders: General Overview,” Elsevier, Reference Module in Biomedical Sciences, 2016).
• X 1 is N or CR 3 ;
• X 3 is N or CR 5 ;
• X 4 is N or CR 6 ; with the proviso that two or three of X 1 , X 2 , X 3 , or
• X 4 are N;
• a 2 is N or CH; [0051] A 3 is NR 11 , O, or S;
• R through R are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (Ci-C4)-alkyl, (Ci-C4)-alkoxy, (Ci-C4)-alkylthio, (Ci-C4)-alkylsulfinyl, or (Ci-C4)-alkylsulfonyl; or two of R 3 through R 6 or two of R 7 through R 10 taken together are (Ci-C4)-alkylenedioxy; and [0053] R 11 is hydrogen, C r C 4 alkyl, or C(0)0-(C r C 4 )-alkyl.
• R x is hydrogen or (Ci-C 6 )-alkyl.
• R 1 is hydrogen.
• R 1 is (Ci-C 6 )-alkyl.
• R 1 is tert-butyl.
• R through R are independently hydrogen, halogen or haloalkyl.
• R through R are independently hydrogen, halogen or trihaloalkyl.
• R through R are hydrogen.
• R through R are independently hydrogen, halogen or haloalkyl. In certain embodiments, R through R are independently hydrogen, halogen or trihaloalkyl.
• R 7 and R 10 are hydrogen.
• R 8 is hydrogen, halogen or haloalkyl. In certain embodiments, R 8 is hydrogen. In certain embodiments, R 8 is halogen. In certain embodiments, R is haloalkyl.
• R 9 is hydrogen, halogen or haloalkyl. In certain embodiments, R 9 is hydrogen. In certain embodiments, R 9 is halogen. In certain embodiments, R 9 is haloalkyl.
• a 1 is NR 11 , S or 01 ⁇ 4. In certain embodiments,
• a 1 is NR 11 or S. In certain embodiments, A 1 is NR 11 . In certain embodiments, A 1 is O. In certain embodiments, A 1 is S.
• A is N or CH. In certain embodiments, A is
• X 1 and X 4 are nitrogen.
• R 4 and R 5 are hydrogen
• X 1 and X 4 are N;
• X 2 is CH
• a 3 is O or S
• R 11 is hydrogen or methyl.
• X 1 and X 4 are N;
• a 1 is NR 11 , O or S
• a 2 is N;
• a 3 is O or S
• R 7 , R 8 and R 10 are independently hydrogen, halogen, or haloalkyl
• exemplary compounds of Formula (P) include the following and salts thereof:
• a 2 is N or CH
• R through R are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (Ci-C4)-alkyl, (C1-C4)- alkoxy, (Ci-C4)-alkylthio, (Ci-C4)-alkylsulfinyl, or (Ci-C4)-alkylsulfonyl;
• X + is a counter ion.
• R 1 is CO2R 2 or C0 2 X + . In certain embodiments, R 1 is CO2R 2 . In certain embodiments, R 1 is C0 2 X + .
• R 2 is hydrogen or (Ci-Ce)-alkyl. In certain embodiments, R 2 is hydrogen or (Ci-C4)-alkyl. In certain embodiments, R 2 is hydrogen or (Ci-C3)-alkyl. In certain embodiments, R 2 is hydrogen, methyl, or ethyl. In certain embodiments, R is hydrogen or methyl. In certain embodiments, R is methyl or ethyl. In certain embodiments, R is methyl. In certain embodiments, R is hydrogen. In certain embodiments, R is (Ci-Ce)-alkyl. In certain embodiments, R is
• R is (Ci-C6)- «-alkyl.
• R is (Ci-C2)-alkyl.
• R is (Ci-C3)-alkyl.
• R is (Ci-C4)-alkyl.
• R is tert-butyl.
• R through R are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C1-C4)- alkyl, (Ci-C4)-alkoxy, (Ci-C4)-alkylthio, (Ci-C4)-alkylsulfinyl, or (C1-C4)- alkylsulfonyl.
• R 3 through R 6 are independently hydrogen, halogen or haloalkyl. In certain embodiments, R 3 through R 6 are independently hydrogen, halogen or trihaloalkyl.
• R and R are hydrogen. In certain embodiments, R , R , and R are hydrogen.
• R 4 is hydrogen, halogen or haloalkyl. In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is halogen. In certain embodiments, R 4 is haloalkyl. I n certain embodiments, R 4 is CF3.
• A is NR , O, S or CH2. In certain embodiments, A is NR , O, or S. In certain embodiments, A is NR , S or CH2. In certain embodiments, A 1 is NR 7 or O. In certain embodiments, A 1 is NR 7 or S. In certain embodiments, A 1 is NR 7 . In certain embodiments, A 1 is O. In certain embodiments, A 1 is S.
• a 2 is N or CH. In certain embodiments, A 2 is
• A is NR , O, or S. In certain embodiments,
• X and X are hydrogen.
• R 1 is CO2R 2 ;
• a 2 is N;
• a 3 is O or S;
• R through R are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (Ci-C4)-alkyl, (C1-C4)- alkoxy, (Ci-C4)-alkylthio, (Ci-C4)-alkylsulfinyl, or (Ci-C4)-alkylsulfonyl; and [0199] R 7 is hydrogen, C1-C4 alkyl, or C(0)0-(Ci-C 4 )-alkyl.
• R 1 is CO2R 2 ;
• R 2 is H or tert-butyl
• a 3 is O or S
• R 1 is CO2R 2 ;
• a 2 is N;
• a 3 is O or S
• the compound of Formula (IP) is pharmaceutically acceptable salt thereof.
• the compound of Formula (PI) is pharmaceutically acceptable salt thereof.
• Z and Z are independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z 1 and Z 2 taken together with the boron atom to which they are bonded form
• X is a substituted or unsubstituted C2-C5 alkylene.
• Z and Z are independently selected from the group consisting of
• X is a substituted or unsubstituted C2-C5 alkylene.
• the aldose reductase inhibitor is a compound of
• X 3 is N or CR 8 ;
• X 4 is N or CR 9 ;
• X 5 is N or CR 10 ;
• X 6 is N or CR 11 ; with the proviso that two or three of X 3 , X 4 , X 5 , or X 6 are N; 1
• Z and Z are independently selected from the group consisting of
• X is a substituted or unsubstituted C2-C5 alkylene
• a 4 is NR 16 , O, S or CH 2 ;
• a 5 is N or CH
• a 6 is NR 16 , O, or S;
• R through R are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (Ci-C4)-alkyl, (Ci-C4)-alkoxy, (Ci-C4)-alkylthio, (Ci-C4)-alkylsulfinyl, or (Ci-C4)-alkylsulfonyl; or two of R 8 through R 11 or two of R 12 through R 15 taken together are (Ci-C4)-alkylenedioxy; and [0362] R 16 is hydrogen, Ci-C 4 alkyl, or C(0)0-(Ci-C 4 )-alkyl.
• Suitable substituents on the C2-C5 alkylene include one or more alkyl, alkoxy, aryl, aryloxy, halo, haloalkyl, haloalkoxy, haloalkylthio.
• a preferred substituted C2-C5 alkylene is substituted ethylene.
• a more preferred substituted C2-C5 alkylene is -C(CH 3 )2C(CH 3 )2-.
• R through R are independently hydrogen, halogen or haloalkyl, for example, R through R are independently hydrogen, halogen or trihaloalkyl (e.g., -CF3).
• R through R are hydrogen.
• R through R are independently hydrogen, halogen or haloalkyl, for example, R through R are independently hydrogen, halogen or trihaloalkyl (e.g., -CF3).
• R and R of Formula (V) are hydrogen.
• R of Formula (V) is hydrogen, halogen or haloalkyl.
• R 13 is hydrogen.
• R 13 is halogen.
• R 13 is haloalkyl.
• R 14 of Formula (V) is hydrogen, halogen or haloalkyl. In certain embodiments, R 14 is hydrogen. In certain embodiments, R 14 is halogen. In certain embodiments, R 14 is haloalkyl.
• C N(Ci-C4)-alkyl.
• a 4 of Formula (V) is NR 16 , S or CH2. In certain embodiments, A 4 is NR 16 or O. In certain embodiments, A 4 is NR 16 or S. In certain embodiments, A 4 is NR 16 . In certain embodiments, A 4 is O. In certain embodiments, A 4 is S.
• a 5 of Formula (V) is N or CH. In certain embodiments, A 4 is N. In certain embodiments, A 4 is CH.
• a 6 of Formula (V) is O or S. In certain embodiments, A 6 is O. In certain embodiments, A 6 is S. [0376] In certain embodiments, X 3 and X 6 of Formula (V) are nitrogen.
• X 3 and X 4 of Formula (V) are nitrogen.
• X 3 and X 5 of Formula (V) are nitrogen.
• X 4 and X 5 of Formula (V) are nitrogen.
• X 4 and X 6 of Formula (V) are nitrogen.
• X 5 and X 6 of Formula (V) are nitrogen.
• R 14 is hydrogen, halogen or trihaloalkyl (e.g., -CF 3 ); and 1
• Z and Z are independently selected from the group consisting of
• X is a substituted or unsubstituted C2-C5 alkylene.
• the aldose reductase inhibitor is a compound of Formula
• Z and Z are independently selected from the group consisting of hydroxy, alkoxy, aryloxy, or Z and Z taken together with the boron atom to which they are bonded form
• X is a substituted or unsubstituted C2-C5 alkylene.
• the AH inhibitor of Formula (VI) is
• alkyl refers to a monovalent aliphatic hydrocarbon radical having a straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof, wherein the radical is optionally substituted at one or more carbons of the straight chain, branched chain, monocyclic moiety, or polycyclic moiety or combinations thereof with one or more substituents at each carbon, where the one or more substituents are independently Ci- Cio alkyl.
• alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbomyl, and the like.
• halogen or “halo-”, as used herein, means chlorine (Cl), fluorine (F), iodine (I) or bromine (Br).
• acyl is used in a broad sense to designate radicals of the type RCO-, in which R represents an organic radical which may be an alkyl, aralkyl, aryl, alicyclic or heterocyclic radical, substituted or unsubstituted, saturated or unsaturated; or, differently defined, the term “acyl” is used to designate broadly the monovalent radicals left when the OH group of the carboxylic radical is removed from the molecule of a carboxylic acid.
• R is an alkyl group, which optionally contains substituents, such as halogen.
• alkoxy is employed to designate an alkoxy with an alkyl group of 1 to 6 carbon atoms.
• alkoxy is employed to designate an alkoxy with an alkyl group of 1 to 3 carbon atoms, such as methoxy or ethoxy.
• cycloalkyl group is used herein to identify cycloalkyl groups having 3-6 carbon atoms preferably cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
• solvate means a compound, or a pharmaceutically acceptable salt thereof, wherein molecules of a suitable solvent are incorporated in the crystal lattice.
• a suitable solvent is physiologically tolerable at the dosage administered. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a “hydrate.”
• a “prodrug” refers to an agent, which is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they are easier to administer than the parent drug. They are bioavailable, for instance, by oral administration whereas the parent drug is either less bioavailable or not bioavailable. The prodrug also has improved solubility in pharmaceutical compositions over the parent drug.
• the compound carries protective groups which are split off by hydrolysis in body fluids, e.g., in the bloodstream, thus releasing active compound or is oxidized or reduced in body fluids to release the compound.
• the term “prodrug” may apply to such functionalities as, for example; the acid functionalities of the compounds of Formula (I).
• Prodrugs may be comprised of structures wherein an acid group is masked, for example, as an ester or amide. Further examples of prodrugs are discussed herein. See also Alexander et al. (/. Med. Chem. 1988, 31, 318), which is incorporated by reference. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a compound that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, and biohydrolyzable phosphate analogues.
• biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, and biohydrolyzable phosphate analogues.
• Biohydrolyzable moieties of a compound of Formula I do not interfere with the biological activity of the compound but can confer upon that compound advantageous properties in vivo, such as uptake, duration of action, or onset of action; or (b) may be biologically inactive but are converted in vivo to the biologically active compound.
• biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
• biohydrolyzable amides include, but are not limited to, lower alkyl amides, a-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
• biohydrolyzable carbamates include, but are not bmited to, lower alkylamines, substituted ethylenediamines, amino acids, hydroxyalkylamines, heterocycbc and heteroaromatic amines, and polyether amines.
• salt includes salts derived from any suitable of organic and inorganic counter ions well known in the art and include, by way of example, hydrochloric acid salt or a hydrobromic acid salt or an alkahne or an acidic salt of the aforementioned amino acids.
• salts derived from inorganic or organic acids including, for example hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2 sulfonic and other acids; and salts derived from inorganic or organic bases including, for example sodium, potassium, calcium, ammonium or tetrafluoroborate.
• Exemplary pharmaceutically acceptable salts are found, for example, in Berge, et al, ( . Pharm. Sci. 1977, 66(1), 1; and U.S. Pat. Nos. 6,570,013 and 4,939,140; each hereby incorporated by reference in its entirety).
• Pharmaceutically acceptable salts are also intended to encompass hemi- salts, wherein the ratio of compound: acid is respectively 2:1.
• Exemplary hemi-salts are those salts derived from acids comprising two carboxylic acid groups, such as malic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, glutaric acid, oxalic acid, adipic acid and citric acid.
• exemplary hemi-salts are those salts derived from diprotic mineral acids such as sulfuric acid.
• Exemplary preferred hemi-salts include, but are not limited to, hemimaleate, hemifumarate, and hemisuccinate.
• the term “acid” contemplates all pharmaceutically acceptable inorganic or organic acids.
• Inorganic acids include mineral acids such as hydrohalic acids, such as hydrobromic and hydrochloric acids, sulfuric acids, phosphoric acids and nitric acids.
• Organic acids include all pharmaceutically acceptable aliphatic, alicyclic and aromatic carboxylic acids, dicarboxylic acids, tricarboxylic acids, and fatty acids.
• Preferred acids are straight chain or branched, saturated or unsaturated Ci- C20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C6-C12 aromatic carboxylic acids.
• acids are carbonic acid, formic acid, fumaric acid, acetic acid, propionic acid, isopropionic acid, valeric acid, alpha-hydroxy acids, such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane sulfonic acid, and salicylic acid.
• dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid and maleic acid.
• An example of a tricarboxylic acid is citric acid.
• Fatty acids include all pharmaceutically acceptable saturated or unsaturated aliphatic or aromatic carboxylic acids having 4 to 24 carbon atoms.
• Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid.
• Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.
• compositions are physiologically acceptable and typically include the active compound and a carrier.
• carrier refers to a diluent, adjuvant, excipient, or vehicle with which a compound is administered.
• Non-limiting examples of such pharmaceutical carriers include liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
• the pharmaceutical carriers may also be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like.
• compositions can be in a desired form, such as a table, capsule, solution, emulsion, suspension, gel, sol, or colloid that is physiologically and/or pharmaceutically acceptable.
• the carrier can include a buffer, for example with alkaline buffers, e.g., ammonium buffer, acidic buffers, e.g., ethanoates, citrates, lactates, acetates, etc., or zwitterionic buffers, such as, glycine, alanine, valine, leucine, isoleucine and phenylalanine, Kreb’s-Ringer buffer, TRIS, MES, ADA, ACES, PIPES, MOPSO, cholamine chloride, MOPS, BES, TES, HEPES, DIPSO, MOBS, TAPSO, acetamidoglycine, TEA, POPSO, HEPPSO, EPS, HEPPS, Tricine, TRIZMA, Glycinamide, Glycyl-glycine, HEPBS, Bicine, TAPS, AMPB, CHES, AMP, AMPSO, CAPSO, CAPS, and CABS.
• a carrier can be a solvent or dispersion medium comprising but not limited to, water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes) and combinations thereof.
• the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof such methods.
• tonicity adjusting agents can be included, such as, for example, sugars, sodium chloride or combinations thereof.
• the composition is isotonic.
• compositions may also include additional ingredients, such as acceptable surfactants, co-solvents, emollients, agents to adjust the pH and osmolarity and/or antioxidants to retard oxidation of one or more component.
• additional ingredients such as acceptable surfactants, co-solvents, emollients, agents to adjust the pH and osmolarity and/or antioxidants to retard oxidation of one or more component.
• compositions can be prepared for administration by any suitable route such as ocular (including periocular and intravitreal administration), oral, parenteral, intranasal, anal, vaginal, topical, subcutaneous, intravenous, intra-arterial, intrathecal and intraperitoneal administration. Accordingly, while intrathecal administration is an option and may be selected by a clinician (e.g., when the aldose reductase inhibitor is not central nervous system penetrant), it is generally preferred that the aldose reductase inhibitor is not administered intrathecally. Oral compositions may be incorporated directly with the food of the diet.
• Preferred carriers for oral administration comprise inert diluents, edible carriers or combinations thereof.
• Examples of pharmaceutically acceptable carriers may include, for example, water or saline solution, polymers such as polyethylene glycol, carbohydrates and derivatives thereof, oils, fatty acids, or alcohols.
• Surfactants such as, for example, detergents, are also suitable for use in the formulations.
• surfactants include polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, polyethylene glycols, benzyl alcohol, mannitol, glycerol, sorbitol or polyoxyethylenated esters of sorbitan; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as methacrylates and others, anionic surfactants, such as alkaline stearates, in particular sodium, potassium or ammonium stearate; calcium stearate or triethanolamine stearate; alkyl sulfates, in particular sodium lauryl sulfate and sodium cetyl sulfate; sodium dodecylbenzenesulphonate or sodium dioctyl sulphosuccinate; or fatty acids, in particular those derived from coconut oil, cationic surfactants, such as water-soluble quaternary ammonium salts of formula
• an oral composition may comprise one or more binders, excipients, disintegration agents, lubricants, flavoring agents, and combinations thereof.
• a composition may comprise one or more of the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, com starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc., or combinations
• Additional formulations which are suitable for other modes of administration include suppositories.
• sterile injectable solutions may be prepared using an appropriate solvent.
• dispersions are prepared by incorporating the various sterilized amino acid components into a sterile vehicle, which contains the basic dispersion medium and/or the other ingredients. Suitable formulation methods for any desired mode of administration are well known in the art (see, generally, Remington’s Pharmaceutical Sciences, 18 th Ed. Mack Printing Company, 1990).
• Typical pharmaceutically acceptable compositions can contain a an AR inhibitor and/or a pharmaceutically acceptable salt thereof at a concentration ranging from about 0.01 to about 2 wt%, such as 0.01 to about 1 wt % or about 0.05 to about 0.5 wt%.
• the composition can be formulated as a solution, suspension, ointment, or a capsule, and the bke.
• the pharmaceutical composition can be prepared as an aqueous solution and can contain additional components, such as preservatives, buffers, tonicity agents, antioxidants, stabilizers, viscosity-modifying ingredients and the bke.
• additional components such as preservatives, buffers, tonicity agents, antioxidants, stabilizers, viscosity-modifying ingredients and the bke.
• Other equivalent modes of administration can be found in U.S. Patent No. 4,939,140.
• the AR inhibitor and pharmaceuticaby acceptable carriers can be sterile.
• suitable pharmaceutical carriers may also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, sibca gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, polyethylene glycol 300, water, ethanol, polysorbate 20, and the bke.
• the present compositions may also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
• compositions of the present disclosure are prepared by methods web-known in pharmaceutics.
• one or more accessory ingredients e.g ., buffers, flavoring agents, surface active agents, and the bke
• the choice of carrier is determined by the solubibty and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.
• the composition is in unit dose form such as a tablet, capsule or single-dose vial. Suitable unit doses, i.e., therapeuticaby effective amounts, may be determined during clinical trials designed appropriately for each of the conditions for which administration of a chosen compound is indicated and will, of course, vary depending on the desired clinical endpoint.
• any of the compounds and/or compositions of the disclosure may be provided in a kit comprising the compounds and/or compositions.
• the compound and/or composition of the disclosure is provided in a kit comprising in the same package or separate package, a carrier and optionally instructions for using the kit for therapeutic or prophylactic end usage.
• the methods described herein include the administration of an AR inhibitor and one more additional therapeutic agents.
• the additional therapeutic agents may be administered before, concurrently with or after the AR inhibitor, but in a manner that provides for overlap of the pharmacological activity of the AR inhibitor and the additional therapeutic agent.
• the additional therapeutic agent can be, for example, second aldose reductase inhibitor, an antioxidant, or both.
• the 2 nd aldose reductase can be a compound described in, for example, in U.S. Patent Nos. 5,677,342; 5,155,259; 4,939,140; US US2006/0293265; and Roy et al, ( Diabetes Research and Clinical Practice, 10, Issue 1, 91 -97, 1990; and references cited therein; each of which hereby incorporated by reference in its entirety.
• Aldose reductase inhibitors include, for example, zopolrestat, epalrestat, ranirestat, berberine and sorbinil, as described in, e.g., U.S. Patent No. 4,939,140; 6,159,976; and 6,570,013.
• the 2 nd aldose reductase inhibitor is selected from ponalrestat, epalrestat, sorbinil or sorbinol, imirestat, AND-138, CT- 112, zopolrestat, zenarestat, BAL-AR18, AD-5467, M-79175, tolrestat, alconil, statil, berberine or SPR-210.
• Other therapeutic agents that can be administered include, for example corticosteroids, e.g., prednisone, methylprednisolone, dexamethasone, or triamcinalone acetinide, or noncorticosteroid anti-inflammatory compounds, such as ibuprofen or flubiproben,.
• corticosteroids e.g., prednisone, methylprednisolone, dexamethasone, or triamcinalone acetinide
• noncorticosteroid anti-inflammatory compounds such as ibuprofen or flubiproben
• vitamins and minerals e.g., zinc, and micronutrients can be co-administered.
• inhibitors of the protein tyrosine kinase pathway which include natural protein tyrosine kinase inhibitors like quercetin, lavendustin A, erbstatin and herbimycin A, and synthetic protein tyrosine kinase inhibitors like tyrphostins (e.g., AG490, AG17, AG213 (RG50864), AG18, AG82, AG494, AG825, AG879, AG1112, AG1296, AG1478, AG126, RG13022, RG14620 and AG555), dihydroxy-and dimethoxybenzylidene malononitrile, analogs of lavendustin A (e.g., AG814 and AG957), quinazolines (e.g., AG1478), 4,5- dianilinophthalimides, and thiazolidinediones, can be co-administered with genistein or an analog, prodrug or pharmaceutically acceptable salt thereof (see
• potentially useful derivatives of genistein include those set forth in Mazurek et al, U. S. Patent No. 5,637,703.
• Selenoindoles (2- thioindoles) and related disulfide selenides such as those described in Dobrusin et al, U. S. Patent No. 5,464,961, are useful protein tyrosine kinase inhibitors.
• Neutralizing proteins to growth factors such as a monoclonal antibody that is specific for a given growth factor, e.g., VEGF (for an example, see Aiello et al, PNAS USA 92: 10457- 10461 (1995)), or phosphotyrosine (Dhar et al, Mol.
• the present disclosure further provides for the use of the compounds of Formula (I)-(VI), or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, in a method of treating a disease state, and/or condition caused by or related to PMM2-CDG.
• Compound B is a potent and selective inhibitor of aldose reductase.
• the AR inhibiting activity of Compound B was demonstrated in a microplate assay using D-glyceraldehyde and NADPH as substrate for aldose reductase in the presence of Compound B at concentrations ranging from 0.1 nM to 10 mM.

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Obesity (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Enzymes And Modification Thereof (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=75437528

Family Applications (1)

Country Status (10)

Cited By (4)

Families Citing this family (1)

Citations (5)

Family Cites Families (4)

• 2020
  • 2020-10-07 CA CA3153108A patent/CA3153108A1/en active Pending
  • 2020-10-07 CN CN202080070704.XA patent/CN114667139B/zh active Active
  • 2020-10-07 JP JP2022521134A patent/JP7778686B2/ja active Active
  • 2020-10-07 IL IL291946A patent/IL291946A/en unknown
  • 2020-10-07 EP EP20875044.8A patent/EP4041219A4/en active Pending
  • 2020-10-07 AU AU2020363699A patent/AU2020363699A1/en active Pending
  • 2020-10-07 BR BR112022005895A patent/BR112022005895A2/pt unknown
  • 2020-10-07 CN CN202510299373.1A patent/CN120114457A/zh active Pending
  • 2020-10-07 MX MX2022004270A patent/MX2022004270A/es unknown
  • 2020-10-07 CN CN202510299188.2A patent/CN120093757A/zh active Pending
  • 2020-10-07 WO PCT/US2020/054607 patent/WO2021071965A1/en not_active Ceased
• 2022
  • 2022-04-07 US US17/715,401 patent/US20220226323A1/en active Pending
• 2025
  • 2025-04-07 JP JP2025063234A patent/JP2025100631A/ja active Pending

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events